TSPAN32 and acute lymphoblastic leukemia: Clinically, ~20–30% of adult ALL and 5% of pediatric ALL are driven by BCR-ABL.22 Firstly, we used public databases (GSE34861) to analyze the clinical correlation between TSPAN32 expression status and the survival of B-ALL patients.